Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetic Neuropathies
Interventions: Vitamin C, Placebo; Dietary Supplement
Lead sponsor: Washington State University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: mifepristone, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: 5% dextrose in water, TZP-101; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more

Conditions: Estrogen Receptor Positive Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer
Interventions: [18F]FES; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 1
Interventions: Parent mentors; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 10 Years to 15 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hyperthyroidism
Interventions: Not listed
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cardiovascular Diseases, Cancer, Type 2 Diabetes, Obesity
Interventions: WIC Fresh Start Program, Existing Online Health Education; Behavioral
Lead sponsor: William Paterson University of New Jersey; Other
Eligibility: Female only
Enrollment: 744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Paterson, New Jersey

Conditions: Acromegaly
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Dietary Intervention Meetings; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: GEM + CGM; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 35 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: Tandem Automated Insulin Delivery System; Device
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 26 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Ovarian Hyperstimulation Syndrome
Interventions: hCG; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Diabetes Mellitus, Type 2
Interventions: CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miramar, Florida • San Antonio, Texas • Tacoma, Washington

Conditions: Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Binimetinib, Encorafenib; Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more

Conditions: Obesity, Overweight, Diabetes
Interventions: Cell Phone, Weekly access to interactive web site, Group; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 12 Years to 16 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Schizophrenia, PreDiabetes
Interventions: Bromocriptine; Drug
Lead sponsor: VA Pittsburgh Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer
Interventions: polymorphism analysis, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Prediabetic State
Interventions: Heat therapy, High-intensity interval training; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 50 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Diabetes Mellitus
Interventions: Mindfulness-Based Stress Reduction (MBSR); Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions: Lorcaserin hydrochloride, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 14,673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 373
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more

Conditions: Diabetes, Obesity, Pre-Diabetes, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 12 Years to 50 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreas Cancer, Pancreas Adenocarcinoma
Interventions: Capecitabine; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions: everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

Parent Mentors to Improve Adherence to Type I Diabetes Care Regimen in Adolescents

Coexisting Thyroid Disease and Hyperparathyroidism

Online WIC Nutrition Education to Promote Farmers' Market Fruit and Vegetable Purchases and Consumption

Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment

The Dietary Guidelines 3 Diets Study

The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication

Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

PACE-iDP: An Intervention for Youth at Risk for Diabetes

Bromocriptine for Patients With Schizophrenia and Prediabetes

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Heat and Exercise in Aging as Therapy (HEAT)

Managing Diabetes Mindfully Study

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

A Study of the Function of Hormones Present In Taste Buds

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer